A retrospective study to assess clinical outcomes of immunotherapy in second and subsequent lines in patients with advanced NSCLC
Latest Information Update: 11 Mar 2021
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer